NASDAQ$CYPH
Cypherpunk Technologies Inc · Q1 2021 earnings
Q1 2021 earnings · · Investor relations
Briefing
Leap Therapeutics reported financial results for the first quarter ended March 31, 2021.
Leap Therapeutics reported a net loss of $9.1 million for the first quarter of 2021, compared to a net loss of $7.2 million for the same period in 2020. License revenues were $0.4 million for both the first quarter of 2021 and 2020.
- Net loss was $9.1 million for the first quarter 2021, compared to $7.2 million for the same period in 2020.
- License revenues were $0.4 million for each of the first quarter 2021 and 2020.
- Research and development expenses were $6.8 million for the first quarter 2021, compared to $4.6 million for the same period in 2020.
- Cash and cash equivalents totaled $43.5 million at March 31, 2021.
Headline financials
Revenue & EPS history
Leap Therapeutics · Revenue · Quarterly
$375K
Forward guidance
This press release contains forward-looking statements within the meaning of the securities act of 1933 and the securities exchange act of 1934, which involve risks and uncertainties.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2021
+11.8%
Avg return
Earnings day
+13.6%
Avg return
5 days after
+11.4%
Avg return
30 days after
50%
17 / 34 earnings
Positive
+389.9%
Q3 2025
Best reaction
-44.0%
Q3 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | +389.9% | +454.8% | +228.8% | |
| Q2 2025 | -28.3% | -15.6% | -11.8% | |
| Q1 2025 | -2.5% | -12.4% | -0.5% | |
| Q4 2024 | +16.9% | -21.4% | +3.1% | |
| Q3 2024 | -11.1% | -14.5% | -9.2% | |
| Q1 2024 | -1.1% | -5.4% | -22.1% | |
| Q4 2023 | -0.5% | +14.0% | +35.7% | |
| Q3 2023 | +13.0% | +32.6% | +128.3% | |
| Q2 2023 | +7.6% | -8.9% | -28.4% | |
| Q1 2023 | +17.1% | +44.4% | +44.4% | |
| Q4 2022 | -12.1% | -0.9% | +11.5% | |
| Q3 2022 | +12.0% | -3.2% | -17.7% | |
| Q2 2022 | +10.0% | -0.8% | +30.0% | |
| Q1 2022 | +34.6% | +25.4% | +10.0% | |
| Q4 2021 | -8.6% | +2.3% | +0.0% | |
| Q3 2021 | +0.4% | +0.8% | +2.9% | |
| Q2 2021 | +0.6% | +3.6% | -12.0% | |
| Q1 2021 | +9.5% | +8.8% | +21.6% | |
| Q4 2020 | +7.9% | +6.1% | -21.1% | |
| Q3 2020 | +0.6% | -3.1% | +21.4% | |
| Q2 2020 | -3.1% | +0.3% | -5.6% | |
| Q1 2020 | +0.0% | +0.4% | +3.1% | |
| Q4 2019 | -4.1% | -14.2% | +20.3% | |
| Q3 2019 | -44.0% | -33.7% | -29.7% | |
| Q2 2019 | -8.9% | -10.2% | +2.5% | |
| Q1 2019 | -1.6% | -6.5% | -0.6% | |
| Q4 2018 | +10.7% | +4.3% | -9.1% | |
| Q3 2018 | -8.8% | -17.1% | -26.8% | |
| Q2 2018 | +2.1% | +6.1% | +8.7% | |
| Q4 2017 | -1.4% | +1.2% | +30.8% | |
| Q3 2017 | -2.1% | +16.9% | +9.2% | |
| Q2 2017 | -5.6% | +2.0% | -6.2% | |
| Q1 2017 | +8.6% | +10.4% | -8.9% | |
| Q4 2016 | +4.0% | -4.7% | -16.2% | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro